Brought to you by 
Cell Genesys acquires rights to cancer therapy from Novartis
29 Aug 2003
Executive Summary
Novartis and its Genetic Therapy Inc. subsidiary (GTI) have licensed Cell Genesys exclusive worldwide rights to GTI's oncolytic (cancer-killing) virus therapy compounds and related intellectual property.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- Includes Contract
- Includes Equity
- R&D and Marketing (Licensing)
- Reverse Licensing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Cell Genesys acquires rights to cancer therapy from Novartis
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice